Daniel Judge to Cardiomyopathies
This is a "connection" page, showing publications Daniel Judge has written about Cardiomyopathies.
Connection Strength
6.969
-
ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022; 18(2):17-26.
Score: 0.743
-
Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity. J Cardiovasc Transl Res. 2022 08; 15(4):689-691.
Score: 0.736
-
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
Score: 0.656
-
Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid. 2017 Jun; 24(2):92-95.
Score: 0.531
-
Genetic evaluation of familial cardiomyopathy. J Cardiovasc Transl Res. 2008 Jun; 1(2):144-54.
Score: 0.284
-
Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006 Oct 03; 48(7):1416-24.
Score: 0.254
-
Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med. 2005 Jan; 2(1):53-7.
Score: 0.226
-
Efficacy and Safety of Angiotensin Receptor Blockers in a Pre-Clinical Model of Arrhythmogenic Cardiomyopathy. Int J Mol Sci. 2022 Nov 11; 23(22).
Score: 0.194
-
The response to cardiac resynchronization therapy in LMNA cardiomyopathy. Eur J Heart Fail. 2022 04; 24(4):685-693.
Score: 0.186
-
Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation. 2021 11 16; 144(20):1600-1611.
Score: 0.180
-
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021 10; 8(5):3875-3884.
Score: 0.179
-
Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation. 2021 05 11; 143(19):1852-1862.
Score: 0.174
-
Exercise triggers CAPN1-mediated AIF truncation, inducing myocyte cell death in arrhythmogenic cardiomyopathy. Sci Transl Med. 2021 02 17; 13(581).
Score: 0.172
-
Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. Am Heart J. 2021 03; 233:122-131.
Score: 0.171
-
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 02; 23(2):277-285.
Score: 0.169
-
Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. Circulation. 2019 10 29; 140(18):1491-1505.
Score: 0.156
-
Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circ Heart Fail. 2019 03; 12(3):e005371.
Score: 0.150
-
Cardiac Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. 2018 10; 142(Suppl 2):S72-S81.
Score: 0.146
-
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
Score: 0.145
-
Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018 09; 20(9):899-909.
Score: 0.143
-
Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J Card Fail. 2018 May; 24(5):281-302.
Score: 0.141
-
Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation. 2017 Sep 26; 136(13):e200-e231.
Score: 0.135
-
Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy. Cell Rep. 2017 01 10; 18(2):571-582.
Score: 0.130
-
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 07 12; 68(2):161-72.
Score: 0.125
-
Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. J Cardiovasc Transl Res. 2015 Jun; 8(4):264-8.
Score: 0.115
-
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015 May; 8(3):519-26.
Score: 0.115
-
Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015 Mar; 8(2):117-27.
Score: 0.114
-
Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol. 2014 Oct; 76(4):541-9.
Score: 0.109
-
Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Transl Med. 2014 Jun 11; 6(240):240ra74.
Score: 0.108
-
Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014 Apr; 7(2):230-6.
Score: 0.106
-
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012 Aug; 164(2):222-228.e1.
Score: 0.095
-
Use of a coronary sinus lead and biventricular ICD to correct a sensing abnormality in a patient with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2006 Mar; 17(3):317-20.
Score: 0.061
-
Extensive cardiac allograft vasculitis and concurrent fat necrosis 6 years after orthotopic heart transplantation. J Heart Lung Transplant. 2007 Nov; 26(11):1212-6.
Score: 0.017